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Abstract Breast cancer patients suffer impairment in
cardiorespiratory fitness after treatment for primary dis-
ease, affecting patients’ health and survival. The aim of this
study was to evaluate the ability of a pragmatic exercise
intervention to improve cardiorespiratory fitness of breast
cancer patients after primary treatment. Between February
2013 and December 2014, 94 women with early stage
(I–III) breast cancer, 1–36 months post-chemotherapy, and
radiotherapy were randomly assigned to an intervention
program (EX) combining supervised aerobic and resistance
exercise (n = 44) or usual care (CON) (n = 45) for
12 weeks. Primary study endpoint was VO2max. Secondary
endpoints were muscle strength, shoulder range of motion,
body composition, and quality of life (QoL). Assessments
were undertaken at baseline, 12-week, and 6-month follow-
ups. Eighty-nine patients aged 29–69 years were assessed
at baseline and 12 weeks. The EX group showed
significant improvements in VO2max, muscle strength,
percent fat, and lean mass (p B 0.001 in all cases) and QoL
compared with usual care (CON). Apart from body com-
position, improvements were maintained for the EX at
6-month follow-up. There were no adverse events during
the testing or exercise intervention program. A combined
exercise intervention produced considerable improvement
in cardiorespiratory fitness, physical function, and quality
of life in breast cancer patients previously treated with
chemotherapy and radiation therapy. Importantly, most of
these benefits were maintained 6 months after ceasing the
supervised exercise intervention.
Keywords Breast cancer  Exercise  Physical capacity 
Lifestyle change  Quality of life
Introduction
Breast cancer is one of the most common cancers and a
leading cause of cancer death in western women [1]. For-
tunately, thanks to both mammogram screening campaigns
and adjuvant therapies, breast cancer survival rates are
increasing, and approximately, 80 % of patients remain
cancer survivors at 5 years [2].
However, breast cancer treatments have serious impli-
cations to health and quality of life [3] with high incidence
of comorbidities following treatments [4]. In addition,
breast cancer patients show lower levels of physical
capacity and mobility compared to women without cancer
of similar age [5]. These impairments to physical capacity,
assessed by maximum oxygen consumption (VO2max) [6],
and changes in body composition (muscle mass loss and fat
mass gain) have been related to poorer survival and higher
risk of metabolic diseases [7].
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It has been reported that exercise is an integrative
intervention that could eliminate, prevent, or reduce these
side effects [8]. However, very few patients are aware of
and follow the exercise recommendations [9, 10] possibly
because clinical oncologists, during early treatment of
breast cancer, may not place emphasis on exercise with this
therapy being relegated to a low priority in the (neo)
adjuvant treatments. Further, access and pragmatic imple-
mentation of exercise for this patient group may be difficult
depending on available facilities and expertise. Finally, the
persistence of benefits of exercise interventions in cancer
survivors has been questioned [11] necessitating trials with
longer term follow-up.
Therefore, the purpose of this study was to examine the
effects of a combined exercise program highly transferable
into best practice supportive care, incorporating aerobic
and resistance exercises, on physical capacity of women
with breast cancer following curative treatments and to
evaluate the maintenance of any benefits at 6-month fol-
low-up.
We hypothesized that a specific exercise intervention
could restore physical capacity of breast cancer patients
who have recently finished adjuvant chemotherapy and
radiotherapy. We designed a randomized controlled trial to
examine the effects of a combined exercise program on the
physical capacity of these patients.
Materials and methods
This was a prospective randomized controlled trial (RCT)
with participants randomly allocated in a 1:1 ratio to one of
two study arms: supervised exercise plus dietary counsel-
ing (EX) or non-intervention control group (CON). Eligible
patients that signed informed consent were randomly
allocated to EX or CON groups by means of a random
number table by an external person not involved in testing
or training the participants [12]. The study was developed
by collaboration between different institutions (Universi-
dad Polite´cnica de Madrid (UPM), Spanish Group of
Cancer Patients (GEPAC), Hospital General Universitario
Gregorio Maran˜o´n, Hospital Universitario Puerta de
Hierro-Majadahonda, and Hospital Madrid Norte-Sanchi-
narro). The intervention was carried out at facilities of the
Physical and Sport Science Institute-INEF (INEF), and the
study was approved by the Human Ethics Committee of
UPM. Prior to any exercise testing or training, each par-
ticipant’s general health and readiness were evaluated
using the PAR-Q [13].
GEPAC staff and medical oncologists from the 4 dif-
ferent institutions undertook patient identification and
recruitment. Inclusion criteria were (1) previously con-
firmed diagnosis of stage I to III breast cancer; (2) age
between 18 and 70 years; (3) at least 1 month and at most
3 years from completion of radiotherapy and chemother-
apy, although they could have been under hormonal or
biological treatments; (4) oncologist approval; and (5)
willing to participate and sign the informed consent.
Exclusion criteria were any other illness or disability
incompatible with exercise (e.g., cardiac condition,
uncontrolled hypertension, severe pulmonary disease,
mental illness, or anticoagulant treatments).
Intervention group
The exercise program was designed and supervised by an
oncologic exercise specialist based on the ACSM guideli-
nes [14]. The exercise program consisted of twice-weekly
supervised exercise sessions combining aerobic and resis-
tance exercise that was increased in intensity over
12 weeks in a familiar and trusted environment, which
promoted socialization between participants. Program
characteristics are presented in Table 1. The intervention
was developed as a pragmatic, nonclinical intervention,
implemented with minimal cost and equipment increasing
the transferability into the clinical environment. It was also
complemented with an education program about exercise
and nutrition guidelines. An initial orientation session on
exercise was conducted outlining current exercise recom-
mendations and the importance of adopting lifestyle
changes to improve outcomes for breast cancer survivors.
The nutrition program consisted of three workshops,
where specific concepts of nutrition and diet were
explained. The first class was on the topic of different
groups of nutrients. The second class was a practical ses-
sion about interpreting food labels and relating measure-
ments of food portions with recommendations for a healthy
diet. The final session addressed the ten best (i.e., rich in
antioxidants) and the ten worst (i.e., rich in animal fat)
dietary components, which might prevent or promote
cancer. The study dieticians ‘recommended patients try to
adopt the Mediterranean diet [15].
Non-intervention group
CON participants were asked to maintain their usual
behavior, without changes in their physical activity levels
or diet. At the end of the twelve weeks, patients in the CON
group were offered to participate in the exercise classes for
ethical considerations and to reduce attrition and
contamination.
Study endpoints
All clinical and patient-reported outcomes were assessed at
baseline and 12 weeks. EX participants were also assessed
372 Breast Cancer Res Treat (2015) 153:371–382
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6 months following completion of the 12-week supervised
intervention to determine if benefits were maintained.
Demographic and descriptive data
Age, marital status, profession, subtype of tumor, type of
resection, lymph node resection, type of endocrine medi-
cation, menopausal status, and physical activity level
(sedentary, defined as less than 30 min of activity per
week; low defined as between 30 and 150 min of activity
per week; moderate defined as between 150 and 300 min
of activity per week; or high defined as over 300 min of
activity per week) [14] were recorded using questionnaires.
Patients were asked not to include the exercise intervention
time in the questionnaires at final assessments to be able to
compare these assessments with the baseline and the fol-
low-up measurements or changes in habitual physical
activity.
Primary outcome: cardiorespiratory capacity
Cardiorespiratory capacity was assessed by estimating the
VO2max of each individual at each test occasion [16]. Each
participant completed a submaximal test using the modi-
fied Bruce protocol performed on a treadmill (PANATA,
Italy) at 85 % of heart rate-reserve (HRR). The Canadian
Society for Exercise Physiology Equation Can [16] was
then applied to predict VO2max.
Secondary outcomes
Muscle strength and shoulder range of motion Isometric
muscle strength was assessed using isometric dynamome-
ters for hand-grip (TKK 5401, Grip-D, Japan) and legs and
back (TKK 5402, Grip-D, Japan) strength. The Strength
Index was obtained by adding all isometric strength values
and dividing the result by the participant’s body weight
[17].
Dynamic muscle strength was assessed using the
8-repetition maximum (RM) test protocol for chest press
and leg extension exercises with subsequent prediction of
1-RM strength following the National Strength and Con-
ditioning Association guidelines [14] and Mayhew for-
mulae [18]. Muscular endurance was determined as
maximal number of repetitions performed at 50 % of 1RM
for the chest press and 70 % of 1RM for the leg extension.
All strength and endurance tests were performed using pin-
loaded resistance machines (PANATA, Italy).
Body composition and anthropometrics Body fat and
lean mass percentage were assessed by electrical bioim-
pedance (BC-601F, Tanita, Japan) [19]. Anthropometric
assessments included weight, height, body mass indexT
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(BMI), waist and hip circumferences, and waist–hip ratio
[17]. Arm circumferences were measured in both limbs
every 10 cm from the metacarpal-phalangeal joints to
15 cm proximal to the lateral epicondyles to assess arm
volume and potential lymphedema [20, 21].
Quality of life (QoL) QoL was assessed using the SF-36
questionnaire which consists of 36 items divided into eight
dimensions that have been interpreted together and sepa-
rately with higher scores on this scale indicating higher
levels of health [22, 23]. The eight subdomains include
physical functioning, role limitation due to physical health,
bodily pain, general health perception, vitality, social
functioning, role limitation due to emotional health and
mental health.
Statistical analysis
Based on the previous work by Jones et al. [6], a difference
in VO2max change of 0.306 (ml/kg*min) between the two
groups is considered clinically relevant and used to esti-
mate the required sample size. Using an alpha level of 0.05,
a final sample size of 86 patients was required to obtain a
statistical power of 80 %. Allowing for 10 % attrition, the
target recruitment was set at 95 patients.
Data were analyzed using SPSS Version 20.0 (IBM,
New York). Confidence interval was set at 95 %, and cri-
teria for significance at p B 0.05 and tailed comparison to
determine significance of the results. Continuous data are
presented as mean ± standard deviation (mean ± SD) and
categorical data as frequencies and percentages in the
tables. Significant differences are presented as standardized
mean difference (SMD), confidence interval of the differ-
ence (CI), and p value (SMD; 95 % CI; p). Groups were
compared in terms of demographic variables by Chi-
squared analysis, if they were categorical, and by ANOVA
if they were continuous. For the other measures, ANCOVA
adjusted for age and baseline values was used to analyse
continuous data and Chi Square for nominal data. ANOVA
was used to compare the 6-month follow-up assessments
for EX participants.
Results
Two hundred and thirty-five women were screened and 94
were enrolled. Women were recruited from February 2013
to December 2014 and randomly assigned to the two study
arms (Fig. 1). No differences in baseline measures were
found between groups, except for age (Table 2).
Eighty-nine women (n = 47 in EX group and n = 47 in
CON group, respectively) completed all of the testing
protocol baseline and 12 weeks (Table 3) and 36 women
from the EX group completed measurements at 6 months
follow-up (Table 4).
Adherence and level of physical activity
The adherence to the program was 87.7 % defined as the
percentage of patients that finally ending the whole pro-
gram, and 86 % of the EX participants returned to perform
the follow-up assessments at 6 months. Participant atten-
dance for the exercise and diet sessions was over 80 %
with 82 % attending all scheduled sessions. With respect to
the number of minutes of physical activity performed per
week, there were significant differences between groups
(v2 = 30.78; p\ 0.001). At baseline, only 36 % of women
in both groups were meeting the recommended 150 min of
physical activity per week as per ASCM guidelines. Fol-
lowing 12 weeks, 91 % of women in EX and only 49 % in
CON were meeting these guidelines (p = 0.001). At
6-month follow-up, 79 % of women in EX were still
meeting the guidelines.
Primary outcome: cardiorespiratory capacity
Following the intervention, VO2max was significantly
higher for EX compared to CON (p\ 0.001). Changes in
VO2max in both groups are presented in Fig. 2. At 6-month
follow-up, EX maintained their VO2max showing no sig-
nificant decline.
Secondary outcomes
Muscle strength and shoulder range of motion
Isometric strength index increased significantly in women
allocated to EX compared with those allocated to CON
(p = 0.004). Further, EX improved maximal strength sig-
nificantly more than CON for chest press (p\ 0.001) and
leg extension (p = 0.001). These differences were also
significant when expressed relative to body weight in both
the chest press (p\ 0.001) and leg extension (p\ 0.001).
Muscle endurance was significantly lower in CON than EX
participants for the chest press (p\ 0.001) and leg exten-
sion (p\ 0.001) at 12 weeks. At 6 months follow-up EX
maintained or improved both (Table 4).
Body composition
EX showed significant reductions in fat mass percentage
(p\ 0.001) and significant increases in lean body mass
(p = 0.001). These changes in body composition were not
maintained by EX during the subsequent 6 months, pre-
senting a significant rise in fat mass (p = 0.001) and a
reduction in lean mass (p = 0.74). No differences between
374 Breast Cancer Res Treat (2015) 153:371–382
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groups in affected arm volume were observed (p[ 0.05)
(results not presented).
Quality of life
EX participants showed significantly higher SF36 scores in
mental and physical dimensions (p = 0.002; p = 0.001,
respectively) and significant improvements in all SF36
subdomains, compared with CON, except for the role
limitation due to emotional health. These changes were
maintained for the EX group at 6-month follow-up.
Discussion
There can be no contention that appropriate exercise is of
physiological, psychological, and survival benefit for breast
cancer patients. However, pragmatic implementation of
exercise into patient support and the longer-term benefits
are much less understood. We found that a low-cost and
specific intervention of combined exercise and dietary
counseling can improve the cardiorespiratory performance
of breast cancer patients, as shown by significant increase
in VO2max capacity. We also examined the effects of the
intervention on muscle strength, body composition, and
quality of life with similar beneficial outcomes.
Previous reviews, including meta-analysis, have repor-
ted results in accord to our VO2max improvements [6, 24].
VO2max has been established as an important predictor of
anthracycline and trastuzumab-induced left ventricular
dysfunction [25, 26], and improvement in VO2max capacity
has been related to reductions in all cause of mortality and
cancer specific mortality [27, 28]. However, this study has
some different and noteworthy points compared with pre-
vious research. First and foremost, our study was devel-
oped and designed as an easy to follow and a low-cost
Screened for eligibility (N=235) 
Ineligible                                  (n = 141) 
Under treatment                                      (n=25) 
Advanced disease                                    (n=14) 
More than 3 years post treatments     (n=15) 
Not willing to parcipate                        (n=87) 
Randomized paents (N=94) 
Allocated to usual care (n=47) Allocated to intervenon (n=47) 
Analyzed (n=44) Analyzed (n=45) 
Total excluded (n=3) 
Work schedule          (n=2) 
Withdrawn                 (n=1) 
Total excluded (n=2) 
Not response              (n=2) 
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Not response                     (n=1)
Fig. 1 CONSORT diagram
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Table 2 Participant characteristics
Variables Frequency N (%) EX frequency CON frequency v2gl P value
Number 94 47 47
Age (years) 49.06 ± 8.75 45.91 ± 8.21 51.87 ± 8.21 0.01
With children 63 (67 %) 32 31
Without children 31 (33 %) 15 16
Marital status v24 = 7.81 0.1
Married 60 (64 %) 35 25
Single with partner 18 (19 %) 8 10
Divorced with partner 6 (6.4 %) 2 4
Widow with partner 0 (0 %) 0 0
Single without partner 7 (7.5 %) 2 5
Divorced without partner 3 (3.1 %) 0 3
Widow without partner 0 (0 %) 0 0
Professional activity v23 = 0.6 0.9
Inactive (B3 h stand) 68 (72.3 %) 35 33
Active ([3 h stand) 20 (21.3 %) 9 11
Housewife 6 (6.4 %) 3 3
Educational level v24 = 4.14 0.39
Basic 8 (8.5 %) 6 2
High school 31 (32.9 %) 17 14
Bachelor 50 (53.2 %) 23 27
Master 3 (3.2 %) 1 2
Ph.D. 2 (2.2 %) 0 2
Type of tumor v23 = 3.94 0.27
Hormon receptor (HR) positive/HER2-negative 53 (56.4 %) 22 31
HR positive/HER2 positive 13 (13.8 %) 7 6
HR negative/HER2 positive 19 (20.2 %) 12 7
Triple negative (HR/HER2negative) 9 (9.6 %) 6 3
Surgery v21 = 0.76 0.38
Lumpectomy 42 (44.6 %) 22 20
Mastectomy 52 (55.4 %) 25 27
Lymph node resection v21 = 0.01 0.93
Yes 57 (60.6 %) 28 29
No 37 (39.4 %) 19 18
General treatment received v23 = 3.13 0.37
Chemotherapy 6 (6.4 %) 2 4
Radiotherapy 12 (12.8 %) 8 4
Chemo ? radio 69 (73.4 %) 32 37
None 7 (7.4 %) 5 2
Specific treatment received v23 = 3.94 0.27
Endocrine therapy 53 (56.4 %) 21 28
Endocrine therapy ?Anti-HER2 13 (13.8 %) 7 6
Anti-HER2 19 (20.2 %) 12 7
None 9 (9.6 %) 6 2
Time since the end of chemo/radio therapy treatments (months) 10.44 ± 8.17 9.63 ± 7.66 11.16 ± 8.58
Receiving at the moment of the study v24 = 3.78 0.44
Anti-estrogen 62 (65.9 %) 34 28
Aromatase inhibitors 13 (13.8 %) 4 9
Herceptin 2 (2.2 %) 1 1
376 Breast Cancer Res Treat (2015) 153:371–382
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intervention, which translated into high adherence and
attendance. Second, the proposed intervention used in our
study is highly transferable to pragmatic implementation in
clinical settings due to the capacity to personalize exercise
sessions and activities, something that has been observed as
an important factor to increase exercise adherence [11, 29].
Other previous studies have carried out controlled inter-
vention developed in lab conditions, which are usually
planed as one to one and low motivation activities [30].
These interventions look for high-quality data but are not
transferable and reproducible in clinical environment.
However, our intervention shows that variables can be
controlled using a motivating methodology based on the
participant necessities [11], mixing resistance, and endur-
ance activities with low-cost material and creating a
transferable and reproducible methodology in the hospitals
and medical centers.
Of high importance, at 6-month follow-up, approxi-
mately 80 % of patients were still performing 150 min of
moderate exercise per week, which meets the ACSM rec-
ommendation at least for aerobic exercise. This can be
considered as an effective change in patient´s lifestyle,
which should provide longer-term health benefit.
Muscle strength was also significantly increased as a
result of the intervention, particularly maximal strength of
the chest muscles that are usually affected by local treat-
ments [31]. Improving or preserving muscle strength is
important because of increased resilience to muscu-
loskeletal injury and muscular strength, playing a funda-
mental role in reducing joint pain and physical limitation,
thus increasing QoL [32, 33]. These results are comple-
mented with a significant improvement in affected shoulder
range of motion. It is estimated that around 60 % of
patients present one upper-body symptom, which affects
breast cancer patients’ daily activities and reduces signifi-
cantly their quality of life [31]. Others have previously
shown similar results to ours [34–40], despite the fact that
most of these studies involved longer interventions. We are
encouraged that shorter interventions of even 12 weeks
appear effective to reduce such treatment side effects
achieving similar improvements.
We also found a significant reduction in body fat mass
percentage and increase in lean mass, changing body
composition toward a more healthy balance, despite the
fact that body weight and BMI did not change significantly.
These are important findings as higher levels of fat mass
and lower levels of muscle mass have been related to
poorer survival [41, 42] and high risk of metabolic diseases
[42–44] indicating the need to restore body composition of
breast cancer survivors after treatments. Previous reviews
have indicated that it is insufficient evidence for the effect
of exercise on body composition in cancer patients [14,
45], but the few studies addressing this topic have found
similar results to ours, suggesting that exercise may be an
efficient tool to restore energy balance and thus improve
body composition [43, 46]. The positive changes in body
composition seen in our study after the 12-week interven-
tion program suggests that such a program could be of
great interest if introduced as a critical component of
patient management, in concordance with the findings of
other studies.
As has been reported in several previous studies [34, 47,
48], women in the exercise group did not present signifi-
cant swelling in the affected arm, further demonstrating
that combined exercise interventions do not increase the
risk of developing or exacerbating lymphedema [49, 50]. It
is hoped that this growing research evidence finally dis-
misses reticence to prescribe resistance training for patients
with lymphoedema.
Apart from improvements in objectively measured out-
comes of physical capacity, the exercise group also showed
significant changes in all subdomains of the SF-36 and in
Table 2 continued
Variables Frequency N (%) EX frequency CON frequency v2gl P value
Others 13 (13.8 %) 6 7
None 4 (4.3 %) 2 2
Menstruation v22 = 4.33 0.11
Yes, regular 8 (8.50 %) 2 6
Yes, irregular 3 (3.20 %) 3 0
No 83 (88.30 %) 42 41
Physical activity at baseline v23 = 5.19 0.16
Sedentary (\30) 22 (23.4 %) 10 12
Low physical activity (30–150) 38 (40.4 %) 20 18
Medium physical activity (150–300) 31 (33 %) 15 16
High physical activity ([300) 3 (3.2 %) 2 1
N number of participants, % percentage, EX exercise group, CON control group
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general QoL compared with usual care, demonstrating the
potential of this intervention to improve patient-reported
outcomes (PROs). Our results are similar to previous
studies and meta-analysis [8, 36, 51–56]. However, this is a
post-treatment study, which may lead to greater changes
than previous studies developed during chemotherapy [57],
suggesting that the best opportunity to modify PROs should
be after cancer (neo) adjuvant treatments.
With regard to longer-term maintenance of adaptations
and benefit, EX retained the improvements in VO2max and
significantly improved muscle strength at 6-month follow-
up. However, body fat mass percentage and lean mass
returned to baseline, which suggests that high levels of
physical activity or high intensity exercise may be neces-
sary to maintain body composition improvements. Only a
small number of studies have followed up exercise inter-
vention achievements in cancer patients [11], suggesting
that more follow-up studies are needed to design effective
interventions to restore physical status of breast cancer
survivors after treatments. In addition, changes in QoL
were maintained after 6-month follow-up, which suggest
that an integrative intervention could be effective to reduce
physical and psychological side effects in a lasting way.
This study had some limitations, and the results have to
be interpreted in this light. Our integrative program included
not only an exercise program but nutritional recommenda-
tions as well. The impact of the dietary recommendations on
the variables measured in our study cannot be established
and separated from the benefits provided by the exercise
program. However, a previous review has suggested that
dietary intervention is insufficient to restore body compo-
sition [58]. It is unlikely, then that the dietary recommen-
dations by themselves could have played a major role in the
observed changes. In addition, self-reported assessments of
questionnaires are normally inferior to objective measures.
However, the used questionnaires have been extensively
validated. Regarding the long-term maintenance of the
benefit, our study follows patients only for 6 months.
Additional studies with longer follow-up are necessary to
establish the maintenance of benefit over multiple years.
Lastly, our patients were well-functioning individuals
mostly motivated to undertake the training program and may
not be representative of all breast cancer patients recently
completing adjuvant chemotherapy and radiotherapy.
Among the strengths of our study, we can mention the
relatively large proportion of patients retained at 12 week
and 6 month assessments, the high compliance to the
intervention, and a very pragmatic, integrative group-based
intervention that was implemented. Further, to our
knowledge, this is the largest exercise intervention in breast
cancer patients ever conducted in Spain.
In conclusion, we report that a combined aerobic and
resistance exercise intervention results in statistically and
clinically significant improvement in VO2max in breast cancer
survivors, as well as improvements in muscle strength, body
composition, quality of life, and fatigue. Much of this benefit
is retained at 6 month post-intervention. Future studies are
needed to establish the ability of this integrative intervention
to maintain the benefits beyond 6 months.
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